Key statistics
As of last trade Vera Therapeutics Inc (VERA:NMQ) traded at 42.59, -16.13% below its 52-week high of 50.78, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.95 |
---|---|
High | 42.69 |
Low | 40.54 |
Bid | 42.50 |
Offer | 42.66 |
Previous close | 40.84 |
Average volume | 668.81k |
---|---|
Shares outstanding | 54.83m |
Free float | 50.53m |
P/E (TTM) | -- |
Market cap | 2.24bn USD |
EPS (TTM) | -2.20 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 17:08 BST.
More ▼
Announcements
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
- Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
- Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
- Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
- Vera Therapeutics to Participate at September Investor Conferences
- Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
- Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
- Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
- Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
More ▼